Crystal Research Associates, LLC Releases Report on Convoy Therapeutics

Share Article

Report details Convoy's business, product development, R&D efforts, and market opportunities.

Transforming the Delivery of Macromolecules into the Skin

Convoy Therapeutics, a subsidiary of ACTUS Biotechnologies, has announced the release of a comprehensive report on the company, compiled by Crystal Research Associates, LLC. The Executive Informational Overview, released on June 17, 2013, details several key points regarding Convoy Therapeutics. Areas covered in the report include recent financial data, growth strategies, patents and other intellectual property, as well as a general overview of the company and its management.

As a transdermal penetration system, the Convoy Therapeutics technology offers a unique delivery option due to its "plug and play" capability. This allows the company to readily reformulate existing molecules (approved and otherwise) increasing skin penetration by orders of magnitude compared to competing technologies. This reduces time to market and improves the patient experience, decreasing dosing regimens and increasing patient compliance.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Dr. John Muraski
Follow us on
Visit website